Norethindrone Acetate And Ethinyl Estradiol Tablet
Product Images NDC 68462-132

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Norethindrone Acetate And Ethinyl Estradiol (NDC 68462-132). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glenmark Pharmaceuticals Inc., Usa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Blister1

Blister1
This is a medication label for Norethindrone Acetate and Ethinyl Estradiol Tablets, used to prevent pregnancy. The label provides instructions for taking the medication on different days of the week. The remaining text is not readable.*
FDA Label Image

Blister2

Blister2
This appears to be a list of the active ingredients in a medication, specifically Norethindrone Acetate and Ethinyl Estradiol Tablets, USP with a dosage of 1mg/0.02mg. The following lines and symbols may represent a calendar with days of the week (Sun-Sat) and some kind of markings or symbols for certain days. However, the meaning of the symbols is not clear or available.*
FDA Label Image

Figure1

Figure1
This text provides a list of studies and their findings comparing the use of combined oral contraceptives (COC) to never using COC or current use of COC. The studies are conducted in different parts of the world and span across several years. The text presents effect estimates in the form of odds ratios, relative risk, and hazard ratios. However, some sections of the text are not readable or are nonsensical, such as the random characters and numbers at the end.*
FDA Label Image

Carton (Image 01)

Carton (Image 01)
This text provides information about a medication called Norethindrone Acetate and Ethinyl Estradiol Tablets. The tablets contain 1 mg of Norethindrone Acetate, USP and 0.02 mg of Ethinyl Estradiol, USP. The recommended dosage is one tablet daily for 21 days, as directed by a physician. The package insert contains full prescribing information. The medication is intended to prevent pregnancy, but does not protect against HIV and other sexually transmitted diseases. The medication should be stored at 20°C to 25°C, and should be kept out of the reach of children. The text also provides information about the manufacturer and contact information for questions.*
FDA Label Image

Logo (Image 02)

FDA Label Image

Structure1 (Image 03)

Structure1 (Image 03)
Ethinyl Estradiol, USP is a pharmaceutical drug used for hormonal contraception and hormone replacement therapy.*
FDA Label Image

Structure2 (Image 04)

Structure2 (Image 04)
This is a pharmaceutical substance called Norethindrone Acetate, which is standardized according to the United States Pharmacopeia (USP) guidelines. No other information is available from the text provided.*
FDA Label Image

Logo1

FDA Label Image

Pouch (Pouch)

Pouch (Pouch)
Norethindrone Acetate and Ethinyl Estradiol Tablets help prevent pregnancy and does not protect against sexually transmitted diseases. Each package contains 21 white to off-white tablets of 1mg/0.02mg of norethindrone acetate and ethinyl estradiol. The recommended dosage is one tablet daily for 21 days. This medication should be kept out of the reach of children as the package is not child-resistant. It should be stored at 20°C to 25°C (68°F to 77°F) with excursions permitted to 15°C to 30°C (59°F to 86°F). The manufacturer is Glenmark Pharmaceuticals limited, Colvale-Bardez, Goa, India. It is manufactured for Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430. For more information, visit their website or call 1 (888) 721-7115. Full prescribing information and detailed patient labeling are included in each package.*
FDA Label Image

Table (Table 2)

Table (Table 2)
This is a mortality rate table that shows circulatory disease rates per 100,000 women years categorized by age, smoking status, and oral contraceptive use. The table shows mortality rates for ever-users (non-smokers) and ever-users (smokers) along with non-smoker XY controls and smoker XY controls. The age groups included are 15-24, 25-34, 35-44, and 45+. The table is adapted from Reference 18 by P.M. Layde and V. Beral.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.